BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:SMARTer health-tech - Dr Gita Khalili Moghaddam
DTSTART:20220309T160000Z
DTEND:20220309T170000Z
UID:TALK171290@talks.cam.ac.uk
CONTACT:Dr Alexandra Huener
DESCRIPTION:Innovation Seminar Series Talk - online\n \n\n"SMARTer health-
 tech"\nDr Gita Khalili Moghaddam\, CEO and founder of TumourVue and GlycoV
 ue\n\nAbout the Speaker\nGita obtained her PhD in Biotechnology from the U
 niversity of Cambridge in 2017. She is currently on secondment at GSK Glob
 al Health until 2023 as a UKRI Innovation Scholar\, taking a leading role 
 in the use of AI in tuberculosis drug development. Gita co-founded TumourV
 ue Ltd in 2018 and GlycoVue Ltd in 2019.\n\nIn 2019\, Gita was awarded a p
 restigious Borysiewicz Biomedical Sciences Fellowship at the University of
  Cambridge in recognition of her outstanding research in the field of biom
 edical engineering. As an academic entrepreneur\, she has been widely reco
 gnised as one of the top 18 women in AI & Data by Innovate UK (2019)\, a B
 ioBeat Mover & Shaker in BioBusiness (2020)\, top contender for Cofinitive
  21toWatch (2021). Gita was recently awarded as  "Business Woman of the Ye
 ar" and  as "Best New Business" with her venture GlycoVue by the SME Cambr
 idgeshire Business Awards 2021.\n\nAbout the Companies\nTumourVue is a dis
 ruptive imaging technology for cancer treatment. The delineation of tumour
  margins is challenging due to existing technical limitations. TumourVue
 ’s innovative solution is a real-time imaging platform where AI creates 
 a colour-coded image of precise tumour margins\, superimposed on the surge
 on’s eye during operation\, to reduce the risk of local recurrence\, imp
 rove survival rates and reduce treatment costs. \n\nGlycoVue represents th
 e accumulation of more than 15 years of experimental research in near-cont
 inuous glucose monitoring in readily accessible biological fluids. GlycoVu
 e combines glucose-responsive smart polymers with advanced holography and 
 AI-enabled smartphone-based instrumentation to create a platform for diabe
 tes self-management. We have fabricated a transparent glucose-sensitive ho
 logram using in-house synthesised boronate monomers as the selective gluco
 se receptors. Preliminary in vitro assessment of its sensitivity\, stabili
 ty and performance appears promising. A smartphone is used to quantify the
  colour response of the hologram with an appropriate algorithm and convert
  it into the blood glucose concentration. \nBoth ventures are spin-offs fr
 om the University of Cambridge.\n \nPlease register for the event here or 
 send an email to ah930@cam.ac.uk\n
LOCATION:Zoom meeting
END:VEVENT
END:VCALENDAR